艾沙度林在腹泻型肠易激综合征患者2期和3期研究中显示无滥用潜力
艾沙度林是FDA批准用于成人腹泻型肠易激综合征(IBS-D)的局部作用混合μ/κ阿片受体激动剂和δ阿片受体拮抗剂。基于1项2期和2项3期随机对照试验的汇总安全性数据,安慰剂组、艾沙度林75 mg组和100 mg组中可能与滥用相关的不良事件总体发生率无显著差异(分别为2.8%、2.7%和4.3%),主观阿片戒断量表评分中位数也无显著差异(分别为3.0、2.0和3.0),未发现艾沙度林有滥用潜力的迹象。
要点
- 艾沙度林75 mg和100 mg组与安慰剂组相比,可能与滥用相关的不良事件总体发生率无显著差异。
- 最常见可能与滥用相关的不良事件为焦虑和嗜睡,每组发生率均低于2%。
- 安慰剂组、75 mg组和100 mg组的主观阿片戒断量表评分中位数无显著差异。
核心结论
- 对艾沙度林(75或100 mg)治疗IBS-D的2期和3期试验数据分析显示,艾沙度林无滥用潜力的迹象。
研究设计与样本
- 1项2期试验(IBS-2001)和2项3期试验(IBS-3001和IBS-3002)为随机对照试验,纳入符合Rome III标准IBS-D的患者。
- 患者接受口服每日两次双盲艾沙度林或安慰剂治疗,疗程为12、26或52周。
- 807例患者接受艾沙度林75 mg,1032例接受100 mg,975例接受安慰剂。
- 安全性数据汇总分析,对可能与滥用相关的不良事件术语进行描述性评估。
- 通过主观阿片戒断量表评估潜在戒断效应,评估时段包括IBS-3001治疗结束后2周和IBS-3002的4周单盲洗脱期。
主要发现
- 可能与滥用相关的不良事件总体发生率在安慰剂组、艾沙度林75 mg组和100 mg组分别为2.8%、2.7%和4.3%,组间无显著差异。
- 最常见可能与滥用相关的不良事件为焦虑和嗜睡,每组发生率均低于2%。
- 主观阿片戒断量表评分中位数在安慰剂组、75 mg组和100 mg组分别为3.0、2.0和3.0,组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Eluxadoline is approved by the Food and Drug Administration for the treatment of adults with irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline is a locally acting mixed μ-opiod and κ-opioid receptor agonist and δ-opioid receptor antagonist. The abuse potential of eluxadoline was evaluated as part of the Phase 2 and 3 clinical trials assessing the efficacy, safety, and tolerability of the drug. METHODS: One Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) randomized controlled trials enrolled patients meeting Rome III criteria for IBS-D. Patients received oral twice-daily double-blind treatment with eluxadoline or placebo for 12, 26, or 52 weeks. The primary end point of these studies was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of days. Safety data were pooled, and specific adverse event terms potentially related to abuse were assessed descriptively. Adverse events reported during a 2-week post-treatment period (IBS-3001) and a 4-week single-blind washout period (IBS-3002) were assessed for signs of opioid withdrawal. Potential withdrawal effects were assessed by using the Subjective Opiate Withdrawal Scale. RESULTS: Overall, 807 and 1032 patients received 1 or more doses of eluxadoline (75 or 100 mg, respectively), and 975 patients received placebo. The overall incidence of adverse events potentially related to abuse did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (2.8%, 2.7%, and 4.3%, respectively). The most common adverse events potentially related to abuse were anxiety and somnolence, which occurred in less than 2% of patients in each group. Median overall Subjective Opiate Withdrawal Scale scores did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (3.0, 2.0, and 3.0, respectively). CONCLUSIONS: In an analysis of data from Phase 2 and Phase 3 trials of eluxadoline (75 or 100 mg) for patients with IBS-D, data revealed no signs of abuse potential for eluxadoline. ClinicalTrials.gov numbers: NCT01130272, NCT01553591, NCT01553747.
引用
- Fant RV, Henningfield JE, Cash BD, et al. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea. Clin Gastroenterol Hepatol. 2017. PMID: 28167156. doi:10.1016/j.cgh.2017.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。